All GLG News Analyses Filed Under: Oncology

Picoplatin + Taxotere (Sanofi) appears in a Phase I trial, to be better than Taxotere alone in reducing PSA levels in metastatic prostate cancer (MPCA.)      (Comparing historical, not head to head data)

Immunologic response translated into improved survivals in 1/2 of the trial subjects!

This data attempts, yet again, to suggest that Provenge is more effective when the cell counts are higher, and more of the cells have CD54 "helper" antigens on their surface. These data are similar to other misleading news releases about Provenge from Dendreon. This is a subset of patients from...

It appears they finally made an attempt to infer causality from a previous result and determine what, if any, treatment effect was implied. I'm quite happy to see this type of analysis but would want to look at all the details, including the raw data if possible, before drawing too many...

Diagnostic tools are availible to identify these adverse effects at an early stage in their clinical development. These tools should mitigate the seriousness of these adverse events.

Patients with rare malignancies, especially those with already metastatic diseases, are being treated with novel oncologic agents.  However, as is being seen with many drugs, the hemodynamic consequences of these agents, in many cases a rise in blood pressure, may lead to cardiovascular consequences. ...

undefined The cardiomyocyte is highly sensitive to perturbations in energy generation, largely because of its huge energy demani (Force, Nat Rev Cancer 2007). Mitochondrial dysfunction and energy depletion seem to be a common theme in cardiotoxicity. However, unlike in anthracycline cardiotoxicity,...

Several agents have recently received FDA approval for the treatment of renal cell carcinoma including Sutent, Nexavar and Torisel.  The recent study describes a 15% rate of cardiovascular toxicities in patients  receiving Sutent including heart failure.  Y+This is a higher rate than...

Avastin faces a substantial hurdle when it goes before the FDA for approval in first line breast cancer therapy.  There has been much debate over the progression free survival benefit (5.5 months) but no overall survival benefit for this agent.  The newly reported European data on Avastin...

New data with low and high dose of Avastin with Taxoter